Table 3. Comparison of nuclear MTA1 scores and other parameters between Non-Recurrent and Recurrent localized PCa.

	NR (n = 50)	R (n = 48)
	Mean ± SE	Mean ± SE	p-value
Localized PCa	0.45 ± 0.06	0.73 ± 0.11	0.03
Gleason sc < 7	0.43 ± 0.11	0.58 ± 0.28	0.62
Gleason sc = 7	0.45 ± 0.10	0.79 ± 0.17	0.10
Gleason sc > 7	0.45 ± 0.12	0.72 ± 0.16	0.19
Initial PSA, ng/ml	13.73 ± 3.47	46.00 ± 18.14	0.09
Follow-up PSA, ng/ml	0.07 ± 0.02	10.06 ± 6.02	0.10
Age, years ± SD	59.90 ± 0.89	61.75 ± 0.89	0.14
	%	%
Capsule invasion,	33.3	45.8	0.22
Positive margins,	40.0	41.7	0.87
Race (AA)	36	33.3	0.78

NR, non-recurrent; R, recurrent; n, number of cases; MTA1, metastasis-associated protein 1; TNS, total nuclear score; SE, standard error; SD, standard deviation; PCa, prostate cancer; sc, score; PSA, prostate-specific antigen; AA, African Americans.

Note: number in bold indicates statistical significance.